AR112403A1 - Formulaciones de ácidos nucleicos altamente concentradas - Google Patents
Formulaciones de ácidos nucleicos altamente concentradasInfo
- Publication number
- AR112403A1 AR112403A1 ARP180102225A AR112403A1 AR 112403 A1 AR112403 A1 AR 112403A1 AR P180102225 A ARP180102225 A AR P180102225A AR 112403 A1 AR112403 A1 AR 112403A1
- Authority
- AR
- Argentina
- Prior art keywords
- syndrome
- disease
- low viscosity
- nucleic acid
- acute
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica de baja viscosidad caracterizada porque comprende un ácido nucleico en una concentración de por lo menos 80 mg/ml. Reivindicación 33: Un dispositivo caracterizado porque es para la administración subcutánea de la formulación de baja viscosidad de cualquiera de las reivindicaciones precedentes. Reivindicación 34: Un método para tratar una enfermedad caracterizado porque comprende administrar la formulación de baja viscosidad de cualquiera de las reivindicaciones 1 - 33, donde la enfermedad se selecciona entre: trombosis, complicaciones relacionadas con transplante de células madre hematopoyéticas (HSCT) incluyendo al síndrome de obstrucción sinusoidal o a la enfermedad vasooclusiva hepática (VOD), enfermedad de injerto contra huésped (GvHD), microangiopatía trombótica asociada a transplante (TA-TMA) o síndrome de neumonía idiopática, otras TMAs que incluyen púrpura trombocitopénica trombótica (TTP) y síndrome urémico hemolítico (HUS), isquemia miocárdica aguda, ACV isquémico, lesión por reperfusión isquémica en el transplante de órganos sólidos, síndrome de dificultad respiratoria aguda (ARDS), crisis vasooclusiva de células falciformes (VOC), síndrome torácico agudo relacionado con células falciformes, coagulación intravascular diseminada (DIC), septicemia, insuficiencia renal, otras enfermedades coronaras o de las arterias periféricas, formas malignas hematológicas o tumores sólidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762540657P | 2017-08-03 | 2017-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112403A1 true AR112403A1 (es) | 2019-10-23 |
Family
ID=63364168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180102225 AR112403A1 (es) | 2017-08-03 | 2018-08-03 | Formulaciones de ácidos nucleicos altamente concentradas |
Country Status (16)
Country | Link |
---|---|
US (2) | US20200261489A1 (es) |
EP (1) | EP3661484A1 (es) |
JP (1) | JP2020530004A (es) |
KR (1) | KR20200121780A (es) |
CN (1) | CN111132663A (es) |
AR (1) | AR112403A1 (es) |
AU (1) | AU2018309068A1 (es) |
BR (1) | BR112020002289A2 (es) |
CA (1) | CA3071544A1 (es) |
CO (1) | CO2020001873A2 (es) |
IL (1) | IL272405A (es) |
MX (1) | MX2020001337A (es) |
SG (1) | SG11202000952PA (es) |
TW (1) | TW201909904A (es) |
WO (1) | WO2019028340A1 (es) |
ZA (1) | ZA202000676B (es) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101948243B1 (ko) | 2012-06-22 | 2019-05-21 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
WO2019213053A1 (en) | 2018-04-30 | 2019-11-07 | Gentium S.R.L. | Methods for treating patients having sinusoidal obstruction syndrome |
US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
US20230190783A1 (en) | 2020-02-28 | 2023-06-22 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
EP4135717A1 (en) | 2020-04-17 | 2023-02-22 | Jazz Pharmaceuticals Ireland Limited | Defibrotide treatment for the prevention of organ rejection and injury |
KR20220151414A (ko) * | 2021-05-06 | 2022-11-15 | 연세대학교 산학협력단 | 허혈성 뇌질환 예방 또는 치료용 약학적 조성물 |
TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2154279A1 (de) | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
IT1043823B (it) | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
US3899481A (en) | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
IT1170214B (it) | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
IT1206341B (it) | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
US4694134A (en) | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
US4693134A (en) | 1985-06-20 | 1987-09-15 | Excelermatic Inc. | High-powered vehicle drive train |
IT1190313B (it) | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
US5223609A (en) | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
IT1223322B (it) | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
IT1231509B (it) | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
US6699985B2 (en) | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
US5977083A (en) | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
IT1252174B (it) | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
ES2251134T3 (es) | 1999-06-08 | 2006-04-16 | Gentium S.P.A. | Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos. |
US8771663B2 (en) | 2000-04-18 | 2014-07-08 | Gentium Spa | Formulation having mobilising activity |
EP1325962A1 (en) | 2001-12-17 | 2003-07-09 | Gentium S.p.A. | A method for determining the biological activity of defibrotide |
ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
WO2005089503A2 (en) * | 2004-03-19 | 2005-09-29 | Progenics Pharmaceuticals, Inc. | Cd4-igg2 formulations |
CA2598613A1 (en) | 2005-03-03 | 2006-09-14 | Gentium S.P.A. | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
EP1872787A1 (en) | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
EP2103689A1 (en) | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
CN101301308A (zh) * | 2008-06-30 | 2008-11-12 | 广东天普生化医药股份有限公司 | Dft在制备治疗和预防弥散性血管内凝血药物中的应用 |
CN101301306A (zh) * | 2008-06-30 | 2008-11-12 | 广东天普生化医药股份有限公司 | Dft在制备治疗和预防休克药物中的应用 |
CN101759767A (zh) | 2008-10-23 | 2010-06-30 | 湖州来色生物基因工程有限公司 | 一种双甘氨肽的合成方法 |
WO2011109365A2 (en) * | 2010-03-01 | 2011-09-09 | Progenics Pharmaceuticals, Inc. | Concentrated protein formulations and uses thereof |
CN107007617A (zh) | 2010-11-12 | 2017-08-04 | 真蒂奥姆责任有限公司 | 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd) |
KR101948243B1 (ko) * | 2012-06-22 | 2019-05-21 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
US20160074515A1 (en) * | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
-
2018
- 2018-08-03 EP EP18759469.2A patent/EP3661484A1/en active Pending
- 2018-08-03 JP JP2020506213A patent/JP2020530004A/ja active Pending
- 2018-08-03 AR ARP180102225 patent/AR112403A1/es unknown
- 2018-08-03 SG SG11202000952PA patent/SG11202000952PA/en unknown
- 2018-08-03 AU AU2018309068A patent/AU2018309068A1/en not_active Abandoned
- 2018-08-03 TW TW107127108A patent/TW201909904A/zh unknown
- 2018-08-03 KR KR1020207006232A patent/KR20200121780A/ko unknown
- 2018-08-03 BR BR112020002289-6A patent/BR112020002289A2/pt not_active Application Discontinuation
- 2018-08-03 CN CN201880061131.7A patent/CN111132663A/zh active Pending
- 2018-08-03 CA CA3071544A patent/CA3071544A1/en not_active Abandoned
- 2018-08-03 MX MX2020001337A patent/MX2020001337A/es unknown
- 2018-08-03 WO PCT/US2018/045152 patent/WO2019028340A1/en unknown
- 2018-08-20 US US16/105,319 patent/US20200261489A1/en not_active Abandoned
-
2020
- 2020-01-31 ZA ZA2020/00676A patent/ZA202000676B/en unknown
- 2020-02-02 IL IL272405A patent/IL272405A/en unknown
- 2020-02-20 CO CONC2020/0001873A patent/CO2020001873A2/es unknown
-
2021
- 2021-07-16 US US17/377,972 patent/US20210338707A1/en active Pending
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
Publication number | Publication date |
---|---|
WO2019028340A1 (en) | 2019-02-07 |
US20200261489A1 (en) | 2020-08-20 |
JP2020530004A (ja) | 2020-10-15 |
IL272405A (en) | 2020-03-31 |
EP3661484A1 (en) | 2020-06-10 |
BR112020002289A2 (pt) | 2020-07-28 |
WO2019028340A9 (en) | 2019-08-08 |
KR20200121780A (ko) | 2020-10-26 |
SG11202000952PA (en) | 2020-02-27 |
CO2020001873A2 (es) | 2020-04-13 |
US20210338707A1 (en) | 2021-11-04 |
ZA202000676B (en) | 2021-01-27 |
TW201909904A (zh) | 2019-03-16 |
CN111132663A (zh) | 2020-05-08 |
CA3071544A1 (en) | 2019-02-07 |
AU2018309068A8 (en) | 2020-02-27 |
AU2018309068A1 (en) | 2020-02-20 |
MX2020001337A (es) | 2020-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112403A1 (es) | Formulaciones de ácidos nucleicos altamente concentradas | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
CL2019002513A1 (es) | Composiciones de limpieza cosmética. | |
RU2017125931A (ru) | Фармацевтическая композиция, содержащая плазминоген, и ее применение | |
AR095964A1 (es) | Formulaciones para la preservación de órganos y tejidos con mayor estabilidad y vida útil | |
CL2018003178A1 (es) | Composición farmacéutica | |
AR083862A1 (es) | Producto de cuidado oral y metodo para su uso y fabricacion | |
UY34854A (es) | Inhibidores del transporte de glucosa | |
ES2577182T3 (es) | Alimento fermentado y método para la producción del mismo | |
PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
CO6210818A2 (es) | Composiciones que comprenden quitosanos para el tratamiento de enfermedades inflamatorias de las uñas | |
PE20142275A1 (es) | Formulacion de anticuerpo il-17 | |
MX356639B (es) | Anticongelante de yema de huevo de pato para la crioconservacion de semen de burro y el metodo de preparacion del mismo. | |
AR080970A1 (es) | Uso de una composicion que contiene fosfolipidos para eliminar acumulaciones por lipolisis subcutanea | |
PE20212158A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso | |
PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
AR075041A1 (es) | Composicion farmaceutica que contiene aleglitazar, proceso, uso. | |
CL2016003063A1 (es) | Composición basada en una solución estabilizada de ingredientes activos | |
PE20130064A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos | |
CL2017003465A1 (es) | Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria. | |
AR113066A1 (es) | Substituto de sal baja en sodio con cloruro de potasio | |
AR112771A1 (es) | Método para evaluar la hidratación bioactiva de un ingrediente o de una mezcla de ingredientes, composiciones cosméticas para la modulación de genes responsables de la hidratación bioactiva de la piel y método para la modulación de la expresión de genes responsables de la hidratación bioactiva de la piel | |
PE20191793A1 (es) | Metodo para preparar una composicion con un bajo contenido de oxigeno disuelto, que comprende paracetamol, y opcionalmente uno o mas aine, y una composicion obtenida de la misma | |
Tang et al. | Observation on efficacy of dexmedetomidine combined with butorphanol in preventing brachial plexus block tourniquet reaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |